Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Aminoacetophenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.54 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.45 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | FADS1 | O60427 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminoacetophenone SCHEMBL29366456 | 0.98 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| 2-Aminoacetophenone SCHEMBL309044 | 0.98 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| 2-Aminoacetophenone SCHEMBL19385986 | 0.95 | ALDH1A1 (0.57) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| 2-Aminoacetophenone SCHEMBL6926008 | 0.89 | ALDH1A1 (0.52) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| 2-Aminoacetophenone SCHEMBL22169185 | 0.89 | MAPT (0.53) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| 2-Aminoacetophenone SCHEMBL27637205 | 0.87 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| Hydrochloric Acid SCHEMBL2647010 | 0.82 | MMP2 (0.45) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| SCHEMBL3794838 | 0.80 | BRD4 (0.56) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| Hydrochloric Acid SCHEMBL6950003 | 0.80 | MMP2 (0.64) | ALDH1A1HSD17B10CFTRMAPTGAA | |
| Hydrochloric Acid SCHEMBL11745887 | 0.80 | MAPT (0.71) | ALDH1A1HSD17B10CFTRMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118549576-A | Organic nitrogen-oxygen metabolism marker for distinguishing wild and cultivated four-big domestic fish and application thereof | 中国水产科学研究院长江水产研究所 | 2024-08-27 | — | — | CN | claimed |
| CN-111423432-B | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | 河南大学 | 2023-01-24 | — | — | CN | claimed |
| CN-115594606-A | Asymmetric synthesis method of threo-2-hydroxy-3-acetamido-4-phenylcarbonyl butyric acid | 成都傲科新技术有限责任公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-20210205260-A1 | MP53 RESCUE COMPONDS AND METHODS OF TREATING A P53 DISORDER | RUI JIN HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE (CN) | 2021-07-08 | — | — | US | claimed |
| EP-3735253-A1 | MP53 RESCUE COMPOUNDS AND METHODS OF TREATING A P53 DISORDER | Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine (CN) | 2020-11-11 | — | — | EP | claimed |
| CN-111423432-A | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | 河南大学 | 2020-07-17 | — | — | CN | claimed |
| WO-2019134650-A1 | MP53 RESCUE COMPOUNDS AND METHODS OF TREATING A P53 DISORDER | RUI JIN HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2019-07-11 | — | — | WO | claimed |
| US-20160193214-A1 | SMALL MOLECULES TO ENHANCE P53 ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-07 | — | — | US | claimed |
| WO-2015021456-A1 | SMALL MOLECULES TO ENHANCE P53 ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-12 | — | — | WO | claimed |
| JP-7309843-A | — | — | None | — | — | JP | disclosed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| CN-113271939-B | Imidazole tetrazine compounds | 伊利诺伊大学董事会 | 2025-03-07 | — | — | CN | disclosed |
| US-12234240-B2 | Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-02-25 | — | — | US | disclosed |
| US-4918188-A | Oxadiazines | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-04-17 | — | — | US | disclosed |
| US-4849516-A | PENICILLIN AND CEPHALOSPORIN ANTIBIOTIC INTERMEDIATES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-07-18 | — | — | US | disclosed |
| US-4835189-A | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | G. D. SEARLE & CO. (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0293899-A1 | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | G.D. Searle & Co. (US) | 1988-12-07 | — | — | EP | disclosed |
| US-4281180-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-07-28 | — | — | US | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | GAA 3792/4885GLA 3646/4885PTGS1 4173/4885 |
| US-12234240-B2 | Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancer | MCL1, IDH1, IDH2 | GAA 1047/4885GLA 470/4885PTGS1 1508/4885 |
| US-20210205260-A1 | MP53 RESCUE COMPONDS AND METHODS OF TREATING A P53 DISORDER | TP53, TP53BP1, RAD50 | GAA 3305/4885GLA 2093/4885PTGS1 2576/4885 |
| US-20160193214-A1 | SMALL MOLECULES TO ENHANCE P53 ACTIVITY | TP53, TP53BP1, MDM2 | GAA 3311/4885GLA 910/4885PTGS1 3467/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | GAA 4737/4885GLA 4535/4885PTGS1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.